CORT
Corcept Therapeutics Incorporat
$52.28
+2.41%
2026-05-08
About Corcept Therapeutics Incorporat
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Key Fundamentals
P/E Ratio
148.29
Forward P/E
31.84
EPS (TTM)
$0.35
ROE
7.2%
Revenue Growth (YoY)
4.9%
Profit Margin
6.2%
Debt/Equity
1.51
Price/Book
8.49
Beta
0.35
Market Cap
$5.57B
Avg Volume (10D)
1.3M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$52.98
60D Low
$28.66
Avg Volume
1.6M
Latest Close
$52.28
Get breakout alerts for CORT
Sign up for Breakout Scanner to receive daily notifications when CORT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Corcept Therapeutics Incorporat (CORT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CORT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CORT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.